How OpenRewrite uses Lossless Semantic Trees to deliver a full-fidelity representation of code, making transformations precise, repeatable, and auditable.

Turns out Java can do serverless right — with GraalVM and Spring, cold starts are tamed and performance finally heats up.

President Trump has delayed imposing tariffs on pharmaceuticals to allow for more negotiations with drug companies. (Francis Chung/Bloomberg News) The Trump administration says it doesn't plan to ...

Generics Awareness Month took center stage at the Mercury Drug Q-Plaza Branch in Cainta recently, where RHEA Generics, in support of the Department of Health (DOH) and in partnership with Mercury Drug ...

Gilead Sciences, Inc. (NASDAQ:GILD) on Monday entered into settlement agreements to resolve the patent litigations with Lupin Ltd., Cipla Ltd. and Laurus Labs Ltd., generic manufacturers that filed ...

The Malta Medicines Authority has moved to reassure the public over the safety, quality, and effectiveness of generic medicines, following remarks by Opposition Leader Alex Borg suggesting a future ...

Gilead Sciences, Inc. (NASDAQ:GILD) announced Monday that it has entered into settlement agreements to resolve patent litigation with generic pharmaceutical companies Lupin Ltd., Cipla Ltd., and ...

Java is one of the most successful and most dreaded technologies in the computer science world. Let's roast this powerful ...

The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems, providing an alternative to comparator products and lowering price ...

In another move designed to reduce the US' reliance on imported medicines, the FDA has launched a pilot of fast-track reviews for generics tested and made in domestic facilities. According to the ...

In an analysis comparing college admission essays generated by artificial intelligence to 30,000 human-written essays from before ChatGPT was released, Cornell University researchers found that AI ...

Thanks to new settlement agreements with three generic drug makers, Gilead Sciences has extended the expected life span of its flagship HIV treatment Biktarvy by as many years. Gilead has struck ...